ClinicalTrials.gg
Not yet recruitingNCT07209267Updated Nov 13, 2026

Baricitinib Curative Repression of HIV-1

A Phase 2 interventional study of Antiretroviral Therapy (ART) and Baricitinib (LY3009104) 2 mg in HIV Infection and HIV, sponsored by Emory University. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Emory University · Phase 2, Interventional, and Treatment

How we know

Updated Nov 13, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in HIV Infections by Emory University — 4 open to participants now, 6 under way, none of them phase 3. HIV Infections · Emory University.

Planned enrollment
13th of 17
35 · median 63
Started
2026
with 1 other
Phase 2
3 of 19
1 open now
Registered
17th of 19
by date

Among the 19 studies in HIV Infections by Emory University, this one is the 13th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 2, and was the 17th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 19 studies in HIV Infections by Emory University are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in HIV Infections by Emory University, or all of them as a file.
02

Study summary

This study is being done to test whether a drug called baricitinib, which blocks specific causes of inflammation, affects HIV-1 viral rebound and viral load levels after HIV treatment is discontinued. Researchers will test the effects of continuing baricitinib in people with HIV before and after discontinuing their antiretroviral therapy. This drug is approved by the Food and Drug Administration (FDA) for other diseases; it is not approved for the treatment of HIV-1. The study team will also investigate any side effects associated with the drug.

Read the detailed description

This study will test whether the medication baricitinib, which reduces inflammation and is already approved for other diseases, can delay the return of HIV after stopping antiretroviral therapy (ART). The goal is to see if baricitinib can safely reduce inflammation and the HIV that is hidden in the body. The study will include adults with HIV who have a suppressed viral load on ART.

Participants will receive ART combined with baricitinib for 25 weeks, followed by baricitinib alone after stopping ART. If the virus returns, the previous ART will be restarted. Each participant will be involved in the study for approximately 12 to 18 months.

Blood and other biological samples may be stored for future research use, with the participant's consent.

03

Conditions studied

  • HIV Infection
  • HIV

Browse trials for

Keywords

  • Baricitinib
  • Antiretroviral Therapy (ART)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented infection
  • On continuous ART for at least 96 weeks before enrollment, with no interruption of ART for 7 consecutive days or longer in the 48 weeks before enrollment.
  • Plasma HIV-1 RNA levels of \<50 copies/mL for at least 96 weeks (a minimum of two measures), and \<50 copies/mL for a sample obtained within 90 days before enrollment.
  • ≥500 cells/mm3 obtained within 90 days prior to enrollment
  • No known history of CD4+ T-cell count nadir \<200 cells/mm3
  • Negative pregnancy test at time of study enrollment
  • Additional laboratory criteria apply.

Exclusion criteria

Exclusion Criteria:

  • \< 18 years of age or > 70 years of age
  • Pregnancy or breastfeeding, as determined by a blood pregnancy test
  • History of AIDS-defining illness, except for recurrent pneumonia.
  • History of progressive multifocal leukoencephalopathy or -associated neurocognitive disease.
  • Untreated latent tuberculosis infection (which will be screened for before entry). If there is a prior positive test, the test does not need to be repeated at screening.
  • History of use of any immunomodulatory medications within 6 months before enrollment, including systemic (>14 days), , anti-cancer, interleukins, systemic interferons, systemic chemotherapy, or other medications that the site investigator feels could have an immunomodulatory effect.
  • History of deep venous thrombosis
  • Cardiovascular disease (Coronary artery disease or history of myocardial infarction, Congestive heart failure with ≤40% per American Heart Association guidelines, history of stroke)
  • History of HIV-associated , including Kaposi's sarcoma, or any lymphoma/leukemia or virus-associated cancers. Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery in the preceding 36 months
  • Major surgery within 8 weeks before screening, or will require major surgery during the study
  • Current or recent (\<4 weeks before screening) clinically serious viral (including COVID-19), bacterial, fungal, or parasitic infection or any other active or recent infection. History of untreated syphilis infection. If a rapid plasma reagin (RPR) test was negative in the 3 months before screening, then an RPR is not needed at screening
  • Symptomatic herpes simplex at the time of screening.
  • Symptomatic herpes zoster infection within 12 weeks before screening.
  • History of disseminated/complicated herpes zoster (for example, ophthalmic zoster or central nervous system (CNS) involvement).
  • Positive test for virus (HBV)
  • Additional exclusion criteria apply
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Baricitinib 2mg

    Adults with well-controlled HIV on ART will be treated for 25 weeks with baricitinib 2 mg per day orally plus their current ART regimen (Step 1). Following 25 weeks of baricitinib plus ART, ART will be interrupted, and the participants will be treated with baricitinib alone for up to 25 weeks (Step 2). If a participant qualifies for ART restart criteria before the end of the maximum 25 weeks of Step 2, they will move to Step 3 early and resume ART, while baricitinib will be discontinued for 25 weeks. Otherwise, participants will remain on baricitinib alone until the end of the 25 weeks of Step 2 and will then resume ART while baricitinib is discontinued for an additional 25 weeks of observation (Step 3).

    Drug: Antiretroviral Therapy (ART) · Drug: Baricitinib (LY3009104) 2 mg

  • Experimental
    Baricitinib 4mg

    Adults with well-controlled HIV on ART will be treated for 25 weeks with baricitinib 4 mg per day orally plus their current ART regimen (Step 1). Following 25 weeks of baricitinib plus ART, ART will be interrupted, and the participants will be treated with baricitinib alone for up to 25 weeks (Step 2). If a participant meets the ART restart criteria before the end of the maximum 25 weeks of Step 2, they will advance to Step 3 early and resume ART, while baricitinib will be discontinued for 25 weeks. Otherwise, participants will remain on baricitinib alone until the end of the 25 weeks of Step 2 and will then resume ART while baricitinib is discontinued for an additional 25 weeks of observation (Step 3).

    Drug: Antiretroviral Therapy (ART) · Drug: Baricitinib (LY3009104) 4 mg

Interventions

  • DrugAntiretroviral Therapy (ART)

    Antiretroviral Therapy (ART): A treatment regimen for HIV infection that uses a combination of antiretroviral drugs to suppress viral replication, reduce HIV-related morbidity, and prevent transmission. In Step 1, participants will continue their current ART regimen for 25 weeks. In Step 2, participants will interrupt ART. In Step 3, participants will restart ART early if they meet the ART restart criteria before the end of Step 2 (a 25-week maximum). Otherwise, they will resume ART at the end of Step 2.

    Also known as: Standard of Care

  • DrugBaricitinibStudies of BaricitinibBaricitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Baricitinib is an orally administered, selective inhibitor of Janus kinase (JAK) 1 and 2. It reduces cytokine-mediated signaling involved in inflammation and immune activation. Baricitinib is FDA-approved for rheumatoid arthritis (RA), atopic dermatitis, and alopecia areata. It has also been authorized for the treatment of COVID-19 in hospitalized patients. During Step 1, Baricitinib will be taken at a dose of 2 mg orally daily for 25 weeks. During Step 2, Baricitinib alone will be continued at a dose of 2 mg orally daily for up to an additional 25 weeks

    Also known as: Olumiant

  • DrugBaricitinibStudies of BaricitinibBaricitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Baricitinib is an orally administered, selective inhibitor of Janus kinase (JAK) 1 and 2. It reduces cytokine-mediated signaling involved in inflammation and immune activation. Baricitinib is FDA-approved for rheumatoid arthritis (RA), atopic dermatitis, and alopecia areata. It has also been authorized for the treatment of COVID-19 in hospitalized patients. During Step 1, Baricitinib will be taken at a dose of 4 mg orally daily for 25 weeks. During Step 2, Baricitinib alone will be continued at a dose of 4 mg orally daily for up to an additional 25 weeks

    Also known as: Olumiant

06

What researchers measure

Primary outcomes

  1. Time to restart ART

    Time to restart ART will be defined by a plasma HIV-1 RNA viral load greater than or equal to 1000 copies/mL following withdrawal of ART during 25 weeks of baricitinib treatment alone (following 25 weeks of baricitinib plus ART).

    Time frame: Up to 25 weeks after the baricitinib treatment alone was started

  2. Number of Participants who discontinued treatment due to adverse events

    Participants who permanently discontinued study drug due to treatment-related adverse events.

    Time frame: Up to 25 weeks after the start of baricitinib alone was started

  3. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants experiencing treatment-emergent adverse events (TEAEs), including serious adverse events.

    Time frame: Up to 25 weeks after the start of baricitinib alone was started

Secondary outcomes

  1. Time to a detectable plasma HIV-1 RNA viral load

    Time to a detectable plasma HIV-1 RNA viral load (defined as greater than the lower limit of quantification) after analytic treatment Interruption (ATI).

    Time frame: Up to 25 weeks after baricitinib alone was started.

Other outcomes

  1. Latent intact HIV reservoir

    Latent intact HIV reservoir as measured in peripheral blood primarily by Intact Proviral DNA Assay (IPDA), integrated HIV-1 DNA (Alu-PCR), cell-associated RNA, and proviral DNA (total HIV cell-associated DNA).

    Time frame: Baseline and up to 25 weeks after baricitinib alone was started.

07

Study locations

2 sites
  • Grady Infectious Diseases Clinic (Ponce Center)
    Atlanta, Georgia 30308, United States
  • Dr. Gavegnano's Laboratory
    Atlanta, Georgia 30322, United States
08

References and documents

Individual participant data

Plan to share: Yes — The research team will share the data that underline the results reported in articles, after deidentification

Supporting information: Study protocol

Time frame: Data will be shared by the research team after the study has been completed.

Access criteria: Requests should be sent directly to the PI via email, summarizing the purpose of utilizing the data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jan 2028, 13 months later.

Of 64 non-industry phase 2 interventional studies under HIV Infections, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 74. This study's planned 13 months is below that.

Counting every sponsor, half of 98 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Oct 6, 2025
StartEst.
Dec 2026was Oct 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Dec 2026
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Start date Oct 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07209267
Lead sponsor
Emory University
Responsible party
Vincent Marconi (Professor of Medicine, Emory University) — Principal investigator
First posted
Oct 6, 2025
Start date
Dec 2026 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Vincent Marconi, MD
Contact
vcmarco@emory.edu
404-616-0673
Vincent Marconi, MD
principal investigator · Emory University
William Tyor, MD
principal investigator · Emory University
Christina Gavegnano, PhD
principal investigator · Emory University
Andrew H Miller, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion